Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma.

Melanoma research - 1 Feb 2015

Anforth Rachael M, Carlos Giuliana R M, Scolyer Richard A, Chou Shaun, Fernandez-Peñas Pablo

Abstract excerpt

LGX818 is a new-generation BRAF inhibitor (BRAFi) that is currently undergoing phase 3 trials for the treatment of BRAF mutant metastatic melanoma patients (NCT01909453). Cutaneous toxicities associated with the administration of BRAF inhibitors are considered to be induced by the paradoxical activation of the mitogen-activated protein kinase pathway in wild-type BRAF cells. Changes in naevi, including new naevi,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Melanoma
Share to Neoplasm Metastasis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nevus, Pigmented

Share to Pigmentation

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Share to Sulfonamides

Source

Identifiers

PMID: 25380183
DOI: 10.1097/CMR.0000000000000127

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma.PMID 25380183Read ↗

Eruptive Melanocytic Nevi Secondary to Encorafenib for BRAF Mutant Metastatic Colorectal Cancer.Semantic proximity Read ↗

Cutaneous adverse events to type I BRAF inhibitors: an analysis of effects associated with each inhibitor and therapeutic time interval to onset.Semantic proximity Read ↗

Dermatological adverse events from BRAF inhibitors: a growing problem.Semantic proximity Read ↗

Dermatologic adverse events associated with targeted therapies for melanoma.Semantic proximity Read ↗

Epidermotropic Metastatic Melanoma Presenting as Eruptive Primary Melanomas.Semantic proximity Read ↗

A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience.Semantic proximity Read ↗

Eruptive naevi associated with encorafenib for metastatic colorectal cancer: two cases.Semantic proximity Read ↗

Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.Semantic proximity Read ↗

BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.Semantic proximity Read ↗

The BRAF and NRAS mutation prevalence in dermoscopic subtypes of acquired naevi reveals constitutive mitogen-activated protein kinase pathway activation.Semantic proximity Read ↗

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.Semantic proximity Read ↗

High incidence of naevi-associated BRAF wild-type melanoma and dysplastic naevi under treatment with the class I BRAF inhibitor vemurafenib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.